银屑病性关节炎（PsA）是一种慢性、免疫介导的炎症性疾病，促炎细胞因子肿瘤坏死因子α（TNF-α）在PsA的发展和进展中起着重要的致病作用。反TNF-α治疗，如单克隆抗体英夫利昔单抗，被用于治疗对传统抗风湿药物没有良好反应的患者。然而，接受反TNF-α治疗可能导致药物诱导性红斑狼疮（DILE），这可能很少伴随着心脏表现。在这里，我们描述了一例罕见的药物诱发性红斑狼疮患者，该患者因PsA和银屑病接受英夫利昔单抗治疗，出现危及生命的急性心包炎和心包填塞。新发生的皮肤疹、新升高的自身免疫指标和穿刺活检结果显示亚急性皮肤狼疮，这些都支持在使用英夫利昔单抗的情况下进行DILE诊断。心包穿刺、秋水仙素和皮质类固醇缓解了症状，英夫利昔单抗被替换为其他治疗方法。本例凸显了及早识别英夫利昔单抗治疗可能产生的严重和不常见的不良反应的重要性。在药物诱导性红斑狼疮的情况下，尤其是出现罕见的心脏并发症时，及时启动适当的治疗，并停用有害制剂至关重要。版权所有 ©2023年，Obeidat等。

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory condition, and the proinflammatory cytokine tumor necrosis factor-α (TNF-α) plays a major pathogenic role in the development and progression of PsA. Anti-TNF-α therapies, such as the monoclonal antibody infliximab, are used to treat patients whose PsA has not responded favorably to conventional anti-rheumatic drugs. However, exposure to anti-TNF-α therapeutics can lead to drug-induced lupus erythematosus (DILE), which may rarely be accompanied by cardiac manifestations. Here, we describe a rare case of drug-induced lupus erythematosus secondary to infliximab therapy for PsA and psoriasis in a patient who presented with life-threatening acute pericarditis and cardiac tamponade. Newly developed skin rashes, newly elevated autoimmune indicators, and punch biopsy results indicating subacute cutaneous lupus collectively supported a DILE diagnosis within the context of infliximab use. Pericardiocentesis, colchicine, and corticosteroids alleviated symptoms, and infliximab was replaced with alternate therapy. This case highlights the importance of early recognition of the possible serious and uncommon adverse reactions from infliximab therapy. Prompt initiation of appropriate treatment and discontinuation of the offending agent are critical in cases of drug-induced lupus erythematosus, particularly when rare cardiac complications occur.Copyright © 2023, Obeidat et al.